Strand Genomics and MediBIC form business partnership - bioinformatics and data mining solutions in Japan

03-Aug-2004

Bangalore, India. Strand genomics, a global Life Sciences informatics company and MediBIC, a leading Japanese pharmacogenomics and pharmaceutical consulting firm announced the formation of a business partnership to provide bioinformatics and data mining solutions in Japan.

Under the terms of the business agreement, MediBIC and Strand will jointly develop products and technologies for their drug discovery and development customers. They will offer products along with customization services, and provide consulting in the areas of genomics, proteomics, clinical studies, predictive ADME/Toxicology, and other pharmaceutical R&D areas.

MediBIC is a bio-venture company that provides various solutions for successful pharmaceutical R&D and medical advancement through genomics and informatics technologies. "MediBIC's success in Japan is quite phenomenal, and Strand is very excited about this partnership. The coming together of our two companies has the potential to deliver great value to the biopharmaceutical industry" said Vijay Chandru Ph. D, Chief Executive Officer, Strand Genomics.

Strand Genomics has emerged as a leading provider of technologies for data mining, image analysis and predictive modeling, making a big impact on the way data is looked at by the life sciences industry. Through its products and technology consulting services, Strand is delivering powerful and effective methods to harness the value in biological and chemistry data.

"One of MediBIC's goal has been to strengthen its informatics and pharmacogenomics capabilities through key strategic partnerships," said Dr. Hashimoto, President and CEO of MediBIC. "This partnership provides us with the platform to offer an integrated discovery and development system. Strand has a strong core capability in applying advanced mathematical solutions to solving life science data analysis problems, and is recognized as a leader in developing in-silico tools. The combined effort of both companies can position us to offer a truly in-silico platform for the entire drug development pipeline.".

https://www.bionity.com/en/news/38915/strand-genomics-and-medibic-form-business-partnership-bioinformatics-and-data-mining-solutions-in-japan.html